YD Bio went public via a SPAC merger with Breeze Holdings Acquisition in a $715m deal.

YD Bio, a biotechnology company, went public via a SPAC merger with Breeze Holdings Acquisition, a blank check company, in a $715m deal. "Since our founding in 2013, YD Bio has evolved from a supplier of clinical trial drugs and health supplements into a dynamic innovator in diagnostics and therapeutics. From pioneering exosome technologies to advancing early cancer detection, our progress reflects years of dedication and transformation. Becoming a publicly traded Nasdaq-listed company enables us to accelerate our mission of delivering innovative solutions that improve lives and advance global health. We are profoundly grateful to the patients who participate in our trials, our dedicated team members, and our investors. We believe this achievement represents the next step in advancing our programs and products, redefining the future of healthcare, and bringing life-changing solutions to patients who need them," Ethan Shen, YD Bio Chairman of the Board and CEO.